BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …

Tumor-associated macrophages (TAMs) and how they are activated play critical roles in
tumor progression and metastasis, and in hepatocellular carcinoma (HCC), they are …

Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment for decades,
especially hepatocellular carcinoma (HCC). Although sorafenib produced substantial …

Objective Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately
present disease progression. Molecular mechanisms underlying acquired resistance are still …

The multikinase inhibitor sorafenib is the only effective drug in advanced cases of
hepatocellular carcinoma (HCC). However, response differs among patients and …

Aim Hepatocellular carcinoma (HCC) is the most common liver malignancy and the second
leading cause of cancer‐related deaths in the world. Sorafenib is the first‐line treatment of …

The increasing incidence of hepatocellular carcinoma (HCC) is of great concern not only in
the United States but throughout the world. Although sorafenib, a multikinase inhibitor with …

Novel therapeutic strategies are needed to treat patients with advanced hepatocellular
carcinoma (HCC). Combination therapy of sorafenib and type I interferon (IFN) has …

Mutations affecting the Wnt/β‑catenin pathway have been identified in 26‑40% of
hepatocellular carcinoma (HCC) cases. Aberrant activation of this pathway leads to …